Key result
Four metabolic syndrome factors linked to ~65% greater MACE risk after PCI versus no factors.
Why the study?
The influence of metabolic syndrome on outcomes after PCI with bare-metal stents is less well studied compared to its known impact after coronary artery bypass grafting.
Does the presence of metabolic syndrome increase the risk of major adverse cardiac events in patients undergoing PCI with bare-metal stents?
Cohort
Does the presence of metabolic syndrome increase the risk of major adverse cardiac events in patients undergoing PCI with bare-metal stents?
Hazard Ratio: 1.65 (95% CI 1.11–2.45)
The presence of metabolic syndrome, particularly with multiple components, significantly increases the risk of major adverse cardiac events following PCI with bare-metal stents.
No takes yet. Share an insight, caveat, or question.
Supports risk stratification by metabolic syndrome burden after bare-metal stent PCI; leaves open whether targeted interventions improve outcomes.
Kalahasti et al. (2011) conducted a cohort in Patients undergoing percutaneous coronary intervention (PCI) with bare-metal stents (BMS). Metabolic syndrome (MetSyn) factors vs. No metabolic syndrome factors was evaluated on Major adverse cardiac events (MACE) (HR 1.65, 95% CI 1.11-2.45). Having four metabolic syndrome factors increased the risk of major adverse cardiac events after PCI with bare-metal stents compared to having no factors (HR 1.65; 95% CI 1.11-2.45).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: